OncoMatch/Clinical Trials/NCT04376866
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
Is NCT04376866 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Toripalimab for recurrent nasopharyngeal carcinoma.
Treatment: Toripalimab — This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT3-4N0-1M0, RT1-4N2-3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Neutrophil ≥ 1.5×10^9 /L and PLT ≥4×10^9 /L and HGB ≥90 g/L
Kidney function
creatinine clearance ≥60 ml/min
Liver function
ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN
Neutrophil ≥ 1.5×10^9 /L and PLT ≥4×10^9 /L and HGB ≥90 g/L; With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN); With normal renal function test ( creatinine clearance ≥60 ml/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify